(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 September 2015 (11.09.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/134911 A1

(51) International Patent Classification:
A61K 31/7068 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2015/019262

(22) International Filing Date:
6 March 2015 (06.03.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/949,215 6 March 2014 (06.03.2014) US

(71) Applicant: **TARIS BIOMEDICAL LLC** [US/US]; 99 Hayden Avenue, Suite 100, Lexington, Massachusetts 02421 (US).

(72) Inventors: **GIESING, Dennis**; 4421 SW Gull Point Drive, Lee's Summit, Missouri 64082 (US). **LEE, Heejin**; 1103 Albion Road, Bedford, Massachusetts 01730 (US). **DANIEL, Karen**; 6 Salisbury Road, Unit 2, Newton, Massachusetts 02458 (US).

(74) Agents: **KING, Kevin W.** et al.; Sutherland Asbill & Brennan LLP, 999 Peachtree Street, NE, Atlanta, Georgia 30309-3996 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: DRUG DELIVERY SYSTEMS AND METHODS FOR TREATMENT OF BLADDER CANCER WITH GEMCITABINE




FIG. 12

(57) Abstract: Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).

WO 2015/134911 A1